Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: The Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial)
作者:
发布时间
2017-04-05
- 浏览0

The American heart journal
675-682页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文